REST Regulates Neuronal Genes in the Aging Brain, Is Absent in AD

VBCN - April 2014 Volume 1, No 1 - Personalized Medicine in Neurology

A new study by a team of researchers led by Bruce A. Yankner, MD, PhD, Professor of Genetics and Neurology, Harvard Medical School, Director of the Harvard Neurodegeneration Training Program, and Codirector of the Paul F. Glenn Laboratories for the Molecular Biology of Aging, has found that a gene regulating protein known as REST (repressor element 1-silencing transcription factor) is involved in protecting the aging brain by reducing oxidative stress, but its absence in old age signals brain disorders, especially Alzheimer’s disease (AD) and potentially other types of dementia (Lu T, et al. Nature. 2014;507:448-454).

The team found that REST confers neuroprotective qualities during aging: it is active during fetal development and then is reactivated during the aging process, reducing oxidative stress and protecting neurons in the brain from stresses, including the various proteins that have been implicated in AD. Furthermore, REST is diminished in early AD and is absent in the brain of patients with full-fledged AD.

REST has been known as a “repressor of neuronal genes during embryonic development that is downregulated once terminal neuronal differentiation has occurred,” the authors wrote. What this new study shows is that “REST is induced in the ageing human brain and regulates a network of genes that mediate cell death, stress resistance and AD pathology. This gene network becomes dysregulated at early stages of AD pathology.” Furthermore, REST “plays a role as a neuroprotective modulator, in part by repressing genes that promote cell death and the pathology of AD,” they note.

REST activates genes that promote neuronal response to stress, a natural mechanism developed to preserve brain function and brain well-being.

However, according to Dr Yankner and colleagues, “REST is induced in the ageing brain and declines in AD. Transcriptional profiling has demonstrated significant changes in the expression of neuronal genes in the prefrontal cortex of the ageing humans.”

Therefore, testing people for the level of REST in their brain could determine who is likely to develop AD.

“One very positive, optimistic note from this study is that it suggests that dementia can be resisted by some people, and it provides the first molecular inkling of how that might occur, “ Dr Yankner said in an interview with the Boston Globe.

Developing a test that shows who has low levels of REST may be the first step to developing preventive therapies for AD.

Related Items
Should Whole-Exome Sequencing Be Integrated into Neurologic Care?
Chase Doyle
VBCN - May 2015 Volume 2, No 1 published on June 1, 2015 in Personalized Medicine in Neurology
Precision Medicine in the Treatment of Epilepsy
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 published on July 29, 2014 in Personalized Medicine in Neurology
Using Genomics in Clinical Practice in Neurology
Wayne Kuznar
VBCN - July 2014 Volume 1, No 2 published on July 29, 2014 in Personalized Medicine in Neurology
Growing Understanding of Genetic Causes of Progressive Myoclonic Epilepsies Improves the Diagnostic Workup
Caroline Helwick
VBCN - April 2014 Volume 1, No 1 published on April 24, 2014 in Personalized Medicine in Neurology
Novel Biomarker Panel May Predict Who Will Develop Cognitive Impairment, Including Alzheimer’s Disease
Rosemary Frei, MSc
VBCN - April 2014 Volume 1, No 1 published on April 24, 2014 in Personalized Medicine in Neurology
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology